The History of Psychedelics in Psychiatry

David E. Nichols; Hannes Walter

doi:10.1055/a-1310-3990

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2021; 54(04): 151-166
DOI: 10.1055/a-1310-3990

Review

The History of Psychedelics in Psychiatry

David E. Nichols

¹Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA

,

Hannes Walter

²Institut für Philosophie, Literatur-, Wissenschafts- und Technikgeschichte, Fachgebiet Wissenschaftsgeschichte, Technische Universität Berlin, Germany

› Author Affiliations

Abstract

Initial interest in the value of psychedelic drugs (“psychotomimetics”) in psychiatry began in the early 20^th century, with explorations of the possibility that mescaline or peyote could produce psychosis-like effects. Over time, interest was focused on whether the effects of psychedelics could inform as to the underlying basis for psychiatric disorders. As research continued, and especially after the discovery of LSD in 1943, increasing interest in a role for psychedelics as adjuncts to psychotherapy began to evolve and became the major focus of work with psychedelics up to the present day.

Key words

hallucinogen - psychedelic - psychotherapy - psychotomimetic - therapy

Full Text

References

References
1 Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective. Can J Psychiatry 2005; 50: 381-388
2 Hoff P. The Kraepelinian tradition. Dialogues Clin Neurosci 2015; 17: 31-41
3 Knauer A, Maloney WJMA. A preliminary note on the psychic action of mescalin, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 1913; 40: 425-436
4 Beringer K. Experimentelle psychosen durch mescalin. Vortrag, gehalten auf der südwestdeutschen psychiaterversammlung in Erlangen 1922. Zeitschrift für die gesamte Neurologie und Psychiatrie 1923; 84: 426-433
5 Fernberger SW. Observations on taking peyote “(Anhalonium Lewinii)”. Am J Psych 1923; 34: 267-270
6 Rouhier A. Le Peyotl (Echinocactus Wttliamsii Lem.) La plante qui fait les yeux emerveilles. Paris: Doin;; 1927
7 Brown AF. Reviews the book, Le Peyotl (Echinocactus Williamsii Lem.): La plante qui fait les yeux emerveilles by Alexander Rouhier (1927). Psychol Bull 1927; 24: 656-658
8 Fernberger SW. Further observations on peyote intoxication. J Abnorm Soc Psychol 1932; 26: 367-378
9 Guttmann E, Maclay WS. Mescalin and depersonalization: therapeutic experiments. J Neurol Psychopathol 1936; 16: 193-212
10 Guttmann E. Artificial Psychoses produced by mescaline. J Ment Sci 1936; 82: 203-221
11 Stockings GT. A clinical study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophenic and other psychotic states. J Mental Sci 1940; 86: 29-47
12 Nichols DE. Dark classics in chemical neuroscience: Lysergic acid diethylamide (LSD). ACS Chem Neurosci 2018; 9: 2331-2343
13 Stoll WA. 11. Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr 1947; 60: 279-323
14 Condrau C. Klinische ergahrungen an geisteskranken mit lysergsäure-diäthylamide. Acta Psychiat Scand 1949; 24: 9-32
15 Stoll A. Ein neues, in sehr kleinen Mengen wirksames Phantastikum. Schweiz Arch Neurol Psychiatr 1949; 64: 483-484
16 Hofmann A. LSD, My Problem Child: Reflections on Sacred Drugs, Mysticism, and Science. Los Angeles, CA: J.P. Tarcher; 1983
17 Busch AK, Johnson WCLSD. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst 1950; 11: 241-243
18 Mayer-Gross W. Experimental psychoses and other mental abnormalities produced by drugs. Br Med J 1951; 2: 317-321
19 Savage C. Lysergic acid diethylamide; a clinical-psychological study. Am J Psychiatry 1952; 108: 896-900
20 Katzenelbogen S, Fang AD. Narcosynthesis effects of sodium amytal, methedrine and L.S.D-25. Dis Nerv Syst 1953; 14: 85-88
21 Anderson EW, Rawnsley K. Clinical studies of lysergic acid diethylamide. Monatsschr Psychiatr Neurol 1954; 128: 38-55
22 Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation. Q J Stud Alcohol 1970; 31: 932-949
23 Hoffer A. A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In: Abramson HA, editor. The Use of LSD in Psychotherapy and Alcoholism. Indianapolis: Bobbs-Merrill; 1967: 343-406
24 Smith CM. A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. Q J Stud Alcohol 1958; 19: 406-417
25 Sandison RA. Psychological aspects of the LSD treatment of the neuroses. J Ment Sci 1954; 100: 508-515
26 Sandison RA, Spencer AM, Whitelaw JD. The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 1954; 100: 491-507
27 Sandison RA, Whitelaw JD. Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 1957; 103: 332-343
28 Denber HC, Merlis S. A note on some therapeutic implications of the mescaline-induced state. Psychiatr Q 1954; 28: 634-640
29 Frederking W. Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis 1955; 121: 262-266
30 Abramson HA. Lysergic acid diethylamide (LSD-25). III. As an adjunct to psychotherapy. J Psychol 1955; 39: 127-155
31 Chwelos N, Blewett DB, Smith CM. et al. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol 1959; 20: 577-590
32 Smith CM. Some reflections on the possible therapeutic effects of the hallucinogens; with special reference to alcoholism. Q J Stud Alcohol 1959; 20: 292-301
33 Eisner BG, Cohen S. Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis 1958; 127: 528-539
34 Cohen S, Eisner BG. Use of lysergic acid diethylamide in a psychotherapeutic setting. AMA Arch Neurol Psychiatry 1959; 81: 615-619
35 Cohen S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 1960; 130: 30-40
36 Lee MA, Shlain B. Acid Dreams: The Complete Social History of LSD: The CIA, The Sixties, and Beyond. New York: Grove Press; 1985
37 Group Interchange. Abramson HA. The Use of LSD in Psychotherapy. New York: Josiah Macy Jr Foundation Publications; 1960: 304
38 Faillace LA. Clinical use of psychotomimetic drugs. Compr Psychiatry 1966; 7: 13-20
39 Passie T. Psycholytic and psychedelic therapy research: A complete international bibliography 1931–1995. Hannover, Germany: Laurentius Publishers; 1997
40 Leuner H. Present state of psycholytic therapy and its possibilities. In: Abramson HA, editor. The Use of of LSD in Psychotherapy and Alcoholism Indianapolis. Bobbs-Merrill; 1967: 101-116
41 Hoffer A. D-lysergic acid diethylamide (LSD): a review of its present status. Clin Pharmacol Ther 1965; 6: 183-255
42 Maclean JR, Macdonald DC, Byrne UP. et al. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol 1961; 22: 34-45
43 Jensen SE. A treatment program for alcoholics in a mental hospital. Q J Stud Alcohol 1962; 23: 315-320
44 Jensen SE, Ramsay R. Treatment of chronic alcoholism with lysergic acid diethylamide. Can Psychiat Assn J 1963; 8: 182-188
45 Unger SM. Mescaline, LSD, psilocybin, and personality change. Psychiatry 1963; 26: 111-125
46 Wallace AF. Stress and rapid personality changes. Int Rec Med Gen Pract Clin 1956; 169: 761-774
47 Oram M. The Trials of Psychedelic Therapy: LSD Psychotherapy in America. Baltimore, MD: Johns Hopkins University Press; 2018
48 Alper K, Beal D, Kaplan CD. A contemporary history of ibogaine in the United States and Europe. In: Alper KR, Glick SD. Ibogaine: Proceedings from the First Internation Conference. First ed.. New York: Academic Press; 2001: 250-282
49 Bastiaans J. Mental liberation facilitated by the use of hallucinogenic drugs. In: Grinspoon L, Bakalar JB. Psychedelic Reflections. New York: Human Sciences Press, Inc; 1983: 143-152
50 Smith CM. Exploratory and controlled studies of lysergide in the treatment of alcoholism. Q J Stud Alcohol 1964; 25: 742-747
51 O’Reilly PO, Funk A. Lsd in chronic alcoholism. Can Psychiatr Assoc J 1964; 9: 258-261
52 Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry 1969; 125: 1352-1357
53 Ludwig AM, Levine J. A controlled comparison of five brief treatment techniques employing lsd, hypnosis, and psychotherapy. Am J Psychother 1965; 19: 417-435
54 Pahnke WN, Kurland AA, Unger S. et al. The experimental use of psychedelic (LSD) psychotherapy. JAMA 1970; 212: 1856-1863
55 Ludwig A, Levine J, Stark L. et al. A clinical study of LSD treatment in alcoholism. Am J Psychiatry 1969; 126: 59-69
56 Ludwig AM, Levine J, Stark LHLSD. et al. Clinical Study of Treatment Efficacy. Springfield, IL: Charles C. Thomas; 1970
57 Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 2014; 7: 157-164
58 Pahnke WN, Kurland AA, Unger S. et al. The experimental use of psychedelic (LSD) psychotherapy. Int Z Klin Pharmakol Ther Toxikol 1971; 4: 446-454
59 Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Arch Gen Psychiatry 1973; 28: 808-814
60 Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012; 26: 994-1002
61 Kast EC, Collins VJ. Lysergic acid diethylamide as an analgesic agent. Anesthes Analg 1964; 43: 285-291
62 Kast E. LSD and the dying patient. Chic Med Sch Q 1966; 26: 80-87
63 Pahnke WN, Kurland AA, Unger S. et al. Psychedelic therapy (utilizing LSD) with cancer patients. J Psychedelic Drugs 1970; 3: 63-75
64 Grof S, Goodman LE, Richards WA. et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 1973; 8: 129-144
65 Grob CS, Danforth AL, Chopra GS. et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011; 68: 71-78
66 Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry 2018; 30: 317-330
67 Griffiths RR, Johnson MW, Carducci MA. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 2016; 30: 1181-1197
68 Anon. Sole U.S. distributor surrenders its right to handle drug LSD. Globe and Mail. Toronto, Canada: The Woodbridge Company 1966: 1
69 Strassman RJ, Qualls CR, Uhlenhuth EH. et al. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994; 51: 98-108
70 Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 1994; 51: 85-97
71 Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101: 131-181
72 Willins DL, Deutch AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997; 27: 79-82
73 Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A. et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 9: 3897-3902
74 Vollenweider FX, Leenders KL, Scharfetter C. et al. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997; 16: 357-372
75 Hermle L, Gouzoulis-Mayfrank E, Spitzer M. Blood flow and cerebral laterality in the mescaline model of psychosis. Pharmacopsychiatry 1998; 31: 85-91
76 Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O. et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999; 20: 565-581
77 Moreno FA, Wiegand CB, Taitano EK. et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1735-1740
78 Griffiths RR, Richards WA, McCann U. et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006; 187: 268-283
79 Ross S, Bossis A, Guss J. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016; 30: 1165-1180
80 Bogenschutz MP, Forcehimes AA, Pommy JA. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015; 29: 289-299
81 Johnson MW, Garcia-Romeu A, Cosimano MP. et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 2014; 28: 983-992
82 Carhart-Harris RL, Bolstridge M, Rucker J. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3: 619-627
83 Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 1984; 172: 577-595
84 Nutt DJ, King LA, Phillips LD. et al. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376: 1558-1565
85 Hendricks PS, Thorne CB, Clark CB. et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 2015; 29: 280-288
86 Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008; 22: 603-620
87 Johnson MW, Hendricks PS, Barrett FS, et al. Classic psychedelics: an integrative review of epidemiology, mystical experience, brain network function, and therapeutics. Pharmacol Ther 2018
88 Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther 2017; 101: 209-219